 BRIDGEWATER, N.J., Jan. 21, 2021 GLOBE NEWSWIRE -- VYNE Therapeutics Inc. Nasdaq: VYNE VYNE or the Company today announced the execution of a contract with a major PBM for its novel AMZEEQ minocycline topical foam, 4 and ZILXI minocycline topical foam, 1.5. AMZEEQ, the first topical minocycline to be approved by the U.S. Food and Drug Administration FDA for any condition, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. ZILXI is indicated for the treatment of inflammatory lesions of rosacea in adults and is the first minocycline product of any form to be approved by the FDA for use in rosacea. 